We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
I Agree
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

GemVax & KAEL reports further positive data from GV1001 Phase II Alzheimer's Disease trial

prnasiaNovember 24, 2020

Tag: GemVax , KAEL , GV1001 , Alzheimer's Disease

PharmaSources Customer Service